Why Vectura group plc and GlaxoSmithKline plc could be the perfect combination

GlaxoSmithKline plc (LON: GSK) and Vectura Group plc (LON: VEC) have many complementary qualities.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in Vectura (LSE: VEC) are charging higher today after the company issued an upbeat trading statement ahead of its AGM to be held later today. The company reported stronger than expected trading and raised revenue expectations for the nine months to December 31.

Vectura is one of the London market’s greatest pharmaceutical success stories. The company’s growth has been explosive over the past few years and after merging with peer Skyepharma in June, the enlarged group is now poised to become a significant player in the industry. Sales across all of the company’s product lines are expanding at a high double-digit rate, and the group has a number of new treatments under development to further growth. Indeed, within today’s update Vectura revealed that sales for its Fruitform product for the six months ended June 30 were 42% ahead of the same period a year earlier at €92.4m from €65.1m a year earlier.

City analysts have been expecting Vectura to report earnings per share of 4.9p this year, putting the group on a forward P/E of 32.5 — these figures haven’t yet been adjusted to reflect today’s optimistic trading statement. At the end of 2015, the company reported a cash balance of £90m before the all-share merger with Skyepharma, which works out at around 10.8p per share.

Vectura’s earnings are growing rapidly, but the company’s premium valuation may put some investors off. If you’re wary of including Vectura in your portfolio, combining it with larger peer GlaxoSmithKline may be the perfect solution.

Old dog, new tricks? 

GlaxoSmithKline (LSE: GSK)  seems to be a love/hate stock. On the one hand, there are those who love the company for its above-average dividend yield and defensive nature. But on the other hand, many are worried about Glaxo’s patent cliff, which has already started to impact sales and income.

Last year Glaxo’s exclusive manufacturing patent for Avodart expired. The treatment for an enlarged prostate gland was generating sales of $973m for the company at its peak in 2010. And next year, it’s expected that generic versions of Glaxo’s blockbuster Advair treatment will hit the market. Last year, Advair accounted for 13% of overall group sales.

Still, Glaxo is making progress towards replacing these lost revenues. For the first half of 2016, the company reported revenue growth of 6% at constant exchange rates with core operating profit up 14%. The company expects full-year core earnings per share to grow by 11% to 12% at constant exchange rates. City analysts have pencilled-in earnings per share growth of 27% for the year ending 31 December 2016 and growth of 6% for 2017. Both of these estimates factor-in sterling’s depreciation.

The perfect mix? 

Combining Vectura and Glaxo in your portfolio would give you a strong mix of income and growth. Glaxo’s shares currently support a dividend yield of 5% and trade at a forward P/E of 17. Meanwhile, Vectura’s earnings per share are set to grow by 56% next year to 7.7p, even though the company’s shares look expensive now, this kind of growth deserves a premium valuation.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline and Vectura. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »